

1 **SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the**
2 **San Francisco Bay Area**

3
4 Dianna L. Ng^{*,1,2}, Gregory M. Goldgof^{*,1}, Brian R. Shy^{*,1}, Andrew G. Levine^{*,1}, Joanna
5 Balcerak^{*,1}, Sagar P. Bapat^{*,1}, John Prostko³, Mary Rodgers³, Kelly Coller³, Sandy Pearce³,
6 Sergej Franz⁵, Li Du⁵, Mars Stone^{1,5}, Satish K. Pillai⁵, Alicia Sotomayor-Gonzalez^{1,4}, Venice
7 Servellita^{1,4}, Claudia Sanchez San Martin^{1,4}, Andrea Granados^{1,4}, Dustin R. Glasner^{1,4}, Lucy M.
8 Han^{1,2}, Kent Truong^{1,2}, Naomi Akagi^{1,2}, David N. Nguyen⁶, Neil M. Neumann², Daniel Qazi²,
9 Elaine Hsu¹, Wei Gu¹, Yale A. Santos^{1,4}, Brian Custer⁵, Valerie Green⁷, Phillip Williamson⁷,
10 Nancy K. Hills^{8,9}, Chuanyi M. Lu^{1,10}, Jeffrey D. Whitman¹, Susan Stramer¹¹, Candace Wang^{1,4},
11 Kevin Reyes^{1,4}, Jill M.C. Hakim¹², Kirk Sujishi¹, Fariba Alazzeh¹, Lori Pham¹, Ching-Ying
12 Oon¹, Steve Miller^{1,4}, Theodore Kurtz¹, John Hackett, Jr.³, Graham Simmons^{1,5}, Michael P.
13 Busch^{1,5}, Charles Y. Chiu^{1,4,6,#}

14
15
16 ¹Department of Laboratory Medicine, University of California, San Francisco, San Francisco,
17 CA, USA

18 ²Department of Pathology, University of California, San Francisco, San Francisco, CA, USA

19 ³Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL, USA

20 ⁴UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA

21 ⁵Vitalant Research Institute, San Francisco, CA, USA

22 ⁶Department of Medicine, Division of Infectious Diseases, University of California, San
23 Francisco, San Francisco, CA, USA

24 ⁷Creative Testing Solutions, Tempe, AZ, USA

25 ⁸Department of Neurology, University of California, San Francisco, San Francisco, CA, USA

26 ⁹Department of Epidemiology and Biostatistics, University of California, San Francisco, San
27 Francisco, CA, USA

28 ¹⁰ Lab Medicine Service, San Francisco VA Healthcare System

29 ¹¹American Red Cross, Gaithersburg, MD, USA

30 ¹²Department of Medicine at ZSFG, the Division of HIV, ID & Global Medicine

31

32 *These authors contributed equally to this work.

33 #Corresponding author.

34

35 Correspondence to:

36 Charles Y. Chiu, MD, PhD

37 Department of Laboratory Medicine,

38 185 Berry Street, Campus box 0134, San Francisco, CA 94107

39 E-mail: charles.chiu@ucsf.edu

40 Phone: (415) 514-8219

41

42

43 **ABSTRACT**

44 We report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations.
45 Seropositivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications
46 and 0.1% in 1,000 blood donors. We additionally describe the longitudinal dynamics of
47 immunoglobulin-G, immunoglobulin-M, and *in vitro* neutralizing antibody titers in COVID-19
48 patients. Neutralizing antibodies rise in tandem with immunoglobulin levels following symptom
49 onset, exhibiting median time to seroconversion within one day of each other, and there is >93%
50 positive percent agreement between detection of immunoglobulin-G and neutralizing titers.

51

52 Coronavirus disease 2019 (COVID-19) is a novel respiratory illness caused by the severe acute
53 respiratory syndrome coronavirus 2 (SARS-CoV-2)¹. The symptoms of COVID-19 range from
54 asymptomatic infection to acute respiratory distress syndrome and death, and the COVID-19
55 pandemic has resulted in substantial burdens on healthcare systems worldwide^{2,3}. Given the
56 current state of diagnostic testing which largely relies on molecular techniques, the
57 seroprevalence of SARS-CoV-2-specific antibodies in different populations remains unclear.
58 Accurate and large-scale serologic testing that includes detection of neutralizing antibodies is
59 essential in evaluating spread of infection in the community, informing public health
60 containment efforts, and identifying donors for convalescent plasma therapy trials.

61

62

63 **Performance Characteristics of the Abbott Architect IgG and IgM SARS-CoV-2 Assays**

64 We first assessed the performance of the Abbott Architect SARS-CoV-2 IgG (FDA
65 Emergency Use Authorization (EUA)) and IgM (prototype) assays from a cohort of five
66 outpatients and 38 hospitalized patients at University of California, San Francisco (UCSF)
67 Medical Center and the San Francisco Veterans Affairs (SFVA) Health Care System. These
68 assays are chemiluminescent microparticle immunoassays that target the nucleocapsid and spike
69 proteins, respectively. All patients received care at adult inpatient units or clinics and were RT-
70 PCR positive for SARS-CoV-2 from nasopharyngeal and/or oropharyngeal swab testing (**Figure**
71 **1A, Table S1**). The percentage of patients seroconverting for IgG at weekly time intervals
72 following reported symptom onset reached 94.4% at ≥ 22 days (**Figure 1B**). Correspondingly,
73 IgG assay sensitivity from analysis of all 423 samples increased weekly to reach 96.9% at ≥ 22
74 days, and was 99% when samples from seven immunocompromised patients (see below) were
75 excluded (**Figure 1D, Table 1**). The percentage of patients seroconverting for IgM was also
76 94.4% at ≥ 22 days (**Figure 1E**) and IgM assay sensitivity from analysis of 346 samples was
77 97.9% (98.9% with immunocompromised patients excluded) (**Figure 1G, Table 1**).

78 Of the four patients who had not seroconverted for IgG by the end of 14 days (**Figure**
79 **1B**), two were kidney transplant recipients on tacrolimus and mycophenolate mofetil (MMF)
80 immunosuppressive therapy; one was >90 years old; and one was an asymptomatic patient
81 receiving acute psychiatric care who provided an unreliable history. Both renal transplant
82 recipients were observed to ultimately seroconvert for IgG and IgM. Notably, delayed
83 seroconversion for IgG and IgM was not universal in immunosuppressed patients: three
84 additional solid organ transplant (SOT) recipients on tacrolimus and MMF, as well as one patient
85 with rheumatoid arthritis on methotrexate and infliximab, all seroconverted within two weeks. A
86 further SOT recipient was positive for IgG and IgM in the earliest available serum sample from
87 day 17 post symptom onset (**Figure 2D, E**). We did not have samples beyond day 18 for the
88 remaining two patients. However, as seroconversion was observed as late as three weeks after
89 symptom onset (**Figure 2D, E**), it is possible that analysis of later samples would have
90 demonstrated detectable antibodies in their serum. The one patient who was still IgG negative in
91 the 22+ day time frame (**Figure 1B**) (from a plasma sample collected on day 29) had only mild
92 symptoms and was positive by IgM and neutralizing antibody testing (described below).
93 Conversely, the one patient who was IgM negative in the 22+ day time frame was both IgG and

94 neutralizing antibody positive from a plasma sample collected on day 50 (**Figure 1E**), by which
95 time IgM antibody titers may have waned significantly.

96 To evaluate assay specificity, serum and plasma samples collected by Abbott
97 Laboratories from US blood donors prior to the COVID-19 pandemic (pre-COVID-19) were
98 tested for IgG (n=1,013) and IgM (n=1,492) seroreactivity. Two samples out of 1,013 were
99 positive by IgG testing, yielding a specificity of 99.8% (95% CI: 99.3-100%) (**Figure 1C**),
100 concordant with the 99.9% specificity reported in a study by the University of Washington^{4,5}.
101 Similarly, testing of 235 remnant plasma samples from 163 SARS-CoV-2 PCR-negative UCSF
102 patients collected from late March to early April 2020 resulted in detection of only one positive
103 sample, yielding a specificity of 99.6% (95% CI: 97.7-100%) (**Figure 1H**). The IgG positive
104 sample was from a patient admitted for syncope but who reported a cough of one-month
105 duration, suggesting a potential prior infection with SARS-CoV-2. Six samples out of 1,492 from
106 US blood donors were positive by IgM testing, yielding a specificity of 99.6% (95% CI: 99.2-
107 99.9%) (**Figure 1F**). This was consistent with more limited testing of 39 SARS-CoV-2 PCR
108 negative UCSF patients, none of whom were positive for IgM antibody (**Figure 1I**). Thus, the
109 Architect SARS-CoV-2 IgG and IgM assays demonstrated high sensitivity (96.9%-97.9% at ≥ 22
110 days in a primarily hospitalized patient cohort) and specificity (99.6-99.8% in pre-COVID blood
111 donors), with good correlation ($\rho = 0.65$) between IgG anti-nucleocapsid protein and IgM anti-
112 spike protein seropositivity (**Figure 2A**).

113

114 **Seroprevalence of SARS-CoV-2 in blood donors and patients from the San Francisco Bay** 115 **Area in March 2020**

116 Next, to investigate SARS-CoV-2 seroprevalence in the San Francisco Bay Area, we
117 collected plasma and serum samples from two cohorts of individuals with low suspicion of
118 infection from COVID-19. One cohort consisted of 1,000 individuals who donated blood in
119 March 2020 at blood bank centers throughout the Bay Area (**Figure 1A, Table S2**). Routine
120 blood donor screening was performed to exclude those with self-reported symptoms of acute
121 illness and abnormal vital signs. We detected four IgG positive samples in this cohort, yielding a
122 seroreactivity rate of 0.40% (**Figure 1H**). This cohort was not tested for IgM antibody. We then
123 analyzed the four samples using two orthogonal tests, the VITROS anti-SARS-CoV-2 total
124 antibody assay (Ortho Clinical Diagnostics EUA) and a SARS-CoV-2 pseudovirus neutralization

125 assay (described below). Three of four samples were negative by both the VITROS and
126 neutralization assays, and thus were designated likely false positives by the Architect IgG assay.
127 Thus, the calculated seroprevalence after confirmatory orthogonal testing for Bay Area blood
128 donors in March 2020 was 0.1% (95% CI: 0.00% - 0.56%). The false positive rate in this
129 population of 0.3% is consistent with with the reported specificity of the Architect SARS-CoV-
130 IgG test of 99.6%⁴.

131 The other cohort for evaluating seroprevalence represented a cross-section of patients
132 who received care at adult inpatient units or clinics at the UCSF Medical Center for indications
133 other than COVID-19 respiratory disease (non-COVID-19, never tested for SARS-CoV-2 by
134 RT-PCR) from late March to early April 2020. Remnant samples from 532 blood draws taken
135 from these 387 patients were obtained from UCSF clinical laboratories. Of these 532 samples,
136 five were positive for IgG; strikingly, all five of these samples were from the same patient who
137 had respiratory failure and ground-glass opacities on chest imaging but was never tested for
138 SARS-2-CoV by RT-PCR (**Figure 1H**). IgG seroprevalence in this population was thus 0.26%
139 (95% CI: 0-0.76%). Although only 23 of the 532 remnant samples were able to be subsequently
140 tested for IgM antibodies, importantly, none were positive (**Figure 1I**).

141

142

143 **Longitudinal dynamics of immunoglobulin and neutralizing antibody titers in SARS-CoV-** 144 **2 infected patient**

145 We next analyzed the longitudinal dynamics of plasma IgG (286 samples) and IgM (249
146 samples) levels in our cohort of 43 patients who were positive for SARS-CoV-2 by PCR. As
147 previously reported, IgG and IgM antibody levels were observed to rise approximately in tandem
148 (**Figure 2D, E**)⁶⁻¹⁰. We correlated median IgG, IgM, and neutralizing antibody (described below)
149 levels at the weekly time intervals with severity of disease, and the differences were not
150 statistically significant.

151 Lastly, we sought to correlate IgG and IgM seropositivity with SARS-CoV-2 *in vitro*
152 neutralizing activity against a SARS-CoV-2 pseudovirus (a vesicular stomatitis virus (VSV)
153 pseudotype expressing the SARS-CoV-2 spike protein). Plasma titers that achieved 80%
154 neutralization of pseudovirus infectivity (NT80) were measured by luciferase assay (see
155 Methods). We compared NT80 with IgG and IgM measurements in 54 available plasma samples

156 from 22 of the 43 SARS-CoV-2 PCR positive patients (**Figure 2B, C**). The positive percent
157 agreement (PPA) between NT80 and IgG positivity was 93.8% and the negative percent
158 agreement (NPA) was 75.0% (**Figure 2C**). Results from the NT80 and IgM comparison were
159 similar, with a PPA of 84.8% and NPA of 78.6% (**Figure 2B**). Importantly, neutralizing titers
160 appeared concomitantly in plasma with IgG and IgM positivity (**Figure 2D-G**), correlated well
161 with IgG ($\rho = 0.79$) and IgM ($\rho = 0.77$) levels, and increased over time in parallel with the
162 rise of anti-spike IgM and anti-nucleocapsid IgG antibodies (**Figure 2H-I**).

163

164 **Conclusions**

165 In this study, we provide evidence that seropositive results using the Architect SARS-
166 CoV-2 anti-nucleocapsid protein IgG and anti-spike IgM assays are generally predictive of *in*
167 *vitro* neutralizing capacity. This correlation may have particular relevance for recovered COVID-
168 19 patients and the identification of candidate donors to provide blood for convalescent plasma
169 therapy. However, *in vitro* neutralization activity may not confer protective immunity and the
170 efficacy of convalescent plasma therapy for treatment of COVID-19 disease remains to be
171 determined. Our results also show that the seroprevalence of IgG antibodies against SARS-CoV-
172 2 in blood donors and non-COVID-19 patients seen at a tertiary care hospital in the San
173 Francisco Bay Area from March to April 2020 is very low at 0.10% (95% CI: 0.00% - 0.56%),
174 and 0.26% (0.00% - 0.76%), respectively. These seroprevalence rates in two distinct populations
175 in the San Francisco Bay Area are near the specificity limit of the Architect assay, and are far
176 lower than the specificity limits for many lateral flow immunoassays¹¹. Our findings contrast
177 with those from other community-based studies that reported higher rates of seropositivity in
178 California^{12,13}, and underscore the importance of using a highly accurate test for surveillance
179 studies in low-prevalence populations. They also indicate a very low likelihood of widespread
180 cryptic circulation of SARS-CoV-2 in the Bay Area prior to March 2020, consistent with the low
181 detection rate by direct viral testing of respiratory samples collected during that early time
182 period¹⁴.

183

184 **METHODS**

185 **Study design and Ethics**

186 The study population consisted of patients with available remnant serum and plasma specimens
187 from the clinical laboratories at University of California, San Francisco (UCSF). Samples from
188 patients who were positive or negative by SARS-CoV-2 real-time polymerase chain reaction
189 (RT-PCR) testing of nasopharyngeal, oropharyngeal, and/or pooled nasopharyngeal-
190 oropharyngeal swabs were collected in March – April 2020. Additional samples were collected
191 from randomly selected cohorts of outpatients and hospitalized patients at UCSF during the same
192 time period seen for indications other than COVID-19 respiratory disease (non-COVID). Serum
193 samples from blood donors in the San Francisco Bay Area were collected by Vitalant Research
194 Institute in March 2020. Clinical data for UCSF patients were extracted from electronic health
195 records and entered in a HIPAA (Health Insurance Portability and Accountability Act)-secure
196 REDCap research database. Collected data included demographics, major comorbidities, patient-
197 reported symptom onset date, clinical symptoms and indicators of COVID-19 severity such as
198 admission to the intensive care unit and requirement for mechanical ventilation. This study was
199 approved by the institutional review board (IRB) at UCSF (UCSF IRB #10-02598) as a no-
200 subject contact study with waiver of consent.

201

202 **Serologic testing**

203 The Abbott Architect SARS-CoV-2 IgG assay (FDA Emergency Use Authorization (EUA)) and
204 SARS-CoV-2 IgM (prototype) testing was performed using either serum or plasma samples on
205 the Architect instrument according to the manufacturer instructions⁴. These tests are
206 chemiluminescent microparticle immunoassay reactions that target the nucleocapsid protein (IgG
207 assay) or the spike protein (IgM assay) and measure relative light units that are then used to
208 calculate an index value. At a predefined index value threshold of 0.6 signal-to-cutoff (S/C) ratio
209 for IgM seropositivity and 1.4 S/C for IgG for seropositivity, these assays were found to have
210 specificities of 99.6% - 99.8%.

211

212 The VITROS anti-SARS-CoV-2 total antibody assay approved under FDA Emergency Use
213 Authorization was performed using either serum or plasma samples at Vitalant Research Institute
214 according to the manufacturer instructions¹⁵. The test is a chemiluminescent immunoassay that
215 targets the spike protein and measures relative light units that are then used to calculate an index
216 value. At a predefined index value threshold of 1.0 signal-to-cutoff (S/C) ratio for IgG

217 seropositivity, this assay was found to have a sensitivity of 100% (92.7% - 100%) and specificity
218 of 100% (95% CI = 99.1% - 100.0%).

219

220 **Production of pseudoviruses for the SARS-CoV-2 neutralization assay**

221 VSV Δ G-luciferase-based viruses, in which the glycoprotein (G) gene has been replaced with
222 luciferase, were produced by transient transfection of viral glycoprotein expression plasmids
223 (pCG SARS-CoV-2 Spike, provided courtesy of Stefan Pöhlmann¹⁶, as well as pCAGGS VSV-G
224 or pCAGGS EboGP as controls) or no glycoprotein controls into HEK293T cells by TransIT-
225 2020. Briefly, cells were seeded into 15-cm culture dishes and allowed to attach for 24 hours
226 before transfection with 30 μ g expression plasmid per plate. The transfection medium was
227 changed at approximately 16 hours post-transfection. The expression-enhancing reagent valproic
228 acid (VPA) was added to a final concentration of 3.75 mM, and the cells were incubated for
229 three to four hours. The medium was changed again, and the cells were inoculated with VSV Δ G-
230 luc virus at a multiplicity of infection (MOI) of 0.3 for four hours before the medium was
231 changed again. At about 24 hours post-infection, the supernatants were collected and cleared of
232 debris by filtration through a 0.45- μ m syringe filter.

233

234 **Antibody neutralization**

235 HEK293T cells were transfected with human ACE2 and TMPRSS2 by TransIT-2020. After 24
236 hours cells were plated into black 96-well tissue culture treated plates. Serum or plasma was
237 diluted to 1:20 followed by four subsequent 1:4 dilutions. Per well, 50 μ l of pseudovirus
238 harboring either SARS-CoV-2 S, VSV-G or EboGP (adjusted to result in ~10,000 RLU in target
239 cells) was mixed with 50 μ l of the respective serum or plasma dilution to give a final series of
240 longitudinal serum or plasma dilutions starting at 1:40 and incubated for one hour at 37°C.
241 Controls included wells with VSV Δ G (no envelope), without added serum/plasma, and with
242 serum predetermined to possess or lack neutralizing activity. Subsequently, the 100 μ l mix was
243 added to the target cells (performed in duplicate) and cells were incubated for 24 hours at 37°C.
244 Supernatants were then removed, cells were lysed, and luciferase activity was read as per
245 manufacturer instructions. Results were calculated as a percentage of no serum control. Each
246 plate was qualified by lack of infection with the no envelope control, and performance of

247 positive and negative controls. Non-linear regression curves and 80% neutralization titers
248 (NT80) were calculated in GraphPad Prism.

249

250 **Statistical analysis**

251 We calculated positive percent agreement (PPA), negative percent agreement (NPA), and overall
252 percent agreement (OPA) between the neutralizing antibody result and IgG, assuming IgG to be
253 the gold standard. We then calculated PPA, NPA, and OPA between the neutralizing antibody
254 result and IgM, assuming IgM to be the gold standard. We calculated 95% exact binomial
255 (Clopper-Pearson) confidence intervals for each proportion. IgG, IgM and NT80 levels were
256 non-normally distributed and were summarized using medians and interquartile ranges. We
257 compared antibody levels to dichotomously-defined clinical characteristics at various time points
258 using Wilcoxon rank sum tests. The correlations between age and IgG, IgM, and NT levels were
259 calculated using Spearman non-parametric correlation coefficients. Statistical calculations were
260 performed using python libraries `scipy.stats`, `sklearn.metrics.auc` and `statsmodels.stats` as well as
261 Stata v15.1 (College Station, TX).

262

263

264

Percentage of positive specimens from patients with positive SARS-CoV2 RT-PCR grouped by days since symptom onset and immune status												
Assay	All Patient Samples				Immunocompetent Only				Immunocompromised only			
	Total N	positive	%	95% CI	Total N	positive	%	95% CI	Total N	positive	%	95% CI
Architect SARS-CoV-2 IgG												
Day 1-7	41	12	29.3	23.7 - 35.6	35	10	28.6	22.5 - 35.5	6	2	33.3	16.1 - 55.3
Day 8-14	106	68	64.2	60.5 - 67.7	82	53	64.6	60.4 - 68.7	24	15	62.5	53.5 - 70.7
Day 15-21	113	102	90.3	87.7 - 92.3	77	72	93.5	90.5 - 95.6	36	30	83.3	77.1 - 88.1
Day 22+	163	158	96.9	95.5 - 97.9	102	101	99	97.4 - 99.7	61	57	93.4	89.9 - 95.8
All	423	340	80.4	78.9 - 81.7	296	236	79.7	77.9 - 81.4	127	104	81.9	79.0 - 84.4
Architect SARS-CoV-2 IgM												
Day 1-7	26	10	38.5	30.6 - 47.0	22	9	40.9	32.1 - 50.4	4	1	25.0	6.9 - 54.4
Day 8-14	91	68	74.7	70.9 - 78.1	70	54	77.1	72.8 - 80.9	21	14	66.7	56.9 - 75.2
Day 15-21	83	75	90.4	87.2 - 92.8	53	49	92.5	88.4 - 95.2	30	26	86.7	79.9 - 91.5
Day 22+	146	143	97.9	96.5 - 98.8	91	90	98.9	97.1 - 99.7	55	53	96.4	93.0 - 98.3
All	346	296	85.5	84.1 - 86.9	236	202	85.6	83.7 - 87.2	110	94	85.5	82.5 - 87.9
Antibody Neutralization Assay												
Day 1-7	10	4	40.0	26.1 - 55.5	9	3	33.3	19.6 - 50.2	1	1	100	25.0 - 100
Day 8-14	24	14	58.3	49.4 - 66.8	18	12	66.7	55.9 - 76.0	6	2	33.3	16.1 - 55.3
Day 15-21	10	7	70.0	54.2 - 82.4	6	5	83.3	61.1 - 95.3	4	2	50.0	24.3 - 75.7
Day 22+	14	13	92.9	81.9 - 98.0	9	9	100	85.7 - 100	5	4	80.0	54.6 - 94.4
All	58	38	65.5	60.3 - 70.4	42	29	69.0	62.8 - 74.7	16	9	56.2	44.8 - 67.1

266

267 **Table 1: Clinical sensitivities of the Abbott Architect SARS-CoV-2 IgG and IgM and *in vitro* neutralization assays**

268 Clinical sensitivity of each assay, defined as the percent of samples from RT-PCR confirmed SARS-CoV-2 infected patients that test
 269 positive in each assay. Total numbers of samples, positive samples, and percent positive among total samples with 95% confidence
 270 intervals (CI) are shown for the indicated time frames for samples from all patients (left column), samples from immunocompetent
 271 patients only (middle column), and samples from immunocompromised patients only (right column.) Immunocompromised patients:
 272 six solid organ transplant recipients on tacrolimus and MMF and one rheumatoid arthritis patient on methotrexate and infliximab.

273 **FIGURE LEGENDS**

274

275 **Figure 1: Seroprevalence of Antibodies to SARS-CoV-2**

276 (A) Schematic of testing performed and location of patient populations assessed. (B) IgG S/C
277 ratios for SARS-CoV-2 PCR-positive patient samples for the indicated weekly timeframes post-
278 onset of symptoms (if multiple samples per patient were collected, the sample with the highest
279 S/C value within each time frame is plotted). The percent of patients with positive antibody
280 responses measured within each timeframe is indicated below the graphs. (C) IgG S/C ratios
281 measured in pre-COVID samples; specificity and number of samples is indicated on graph. (D)
282 Receiver operating characteristic (ROC) curves for IgG levels for all samples from SARS-CoV-2
283 PCR-positive patients within the indicated weekly time frames. AUCs for are 0.537 (day 1-7),
284 0.827 (day 8-14), 0.946 (day 15-21), 0.990 (day 22+). (E) IgM S/C ratios, as in (B). (F) IgM S/C
285 ratios measured in pre-COVID samples. (G) ROC curves for IgM levels, as in (D); AUCs are
286 0.720 (day 0-7), 0.955 (day 8-14), 0.970 (day 15-21), 0.999 (day 22+). IgG (H) and IgM (I) S/C
287 ratios were determined for hospitalized patients and outpatients and blood donors on whom
288 SARS-CoV-2 PCR testing was positive or negative or was not performed. Numbers of
289 seroreactive and total individuals tested are shown in tables below the graphs. The circled data
290 points in (H) were additionally tested by the VITROS and neutralization assays. For patients
291 with multiple samples, the single highest S/C value is plotted. In (B), (C), and (H), the dotted
292 line at 1.4 indicates cutoff for IgG positivity; in (E), (F), and (I), the dotted line at 0.6 indicates
293 cutoff for IgM positivity; data points in black and gray are above and below the indicated
294 cutoffs, respectively.

295

296 **Figure 2: Longitudinal dynamics and *in vitro* neutralizing activity of antibodies against**
297 **SARS-CoV-2**

298 (A) IgG and IgM levels for SARS-CoV-2 PCR positive matched patient samples. Percent of data
299 points in each quadrant and positive percent agreement (PPA), negative percent agreement
300 (NPA), and overall percent agreement (OPA) between IgG and IgM are shown. 80%
301 neutralization titers (NT80) plotted against IgM (B) and IgG (C) S/C values. The cutoff for
302 NT80 was a titer level of >40; negative results are non-numeric (<40) and are plotted at 35 for
303 visualization purposes. (D-F), IgM (D) and IgG (E) S/C ratios and NT80 titers (F) for SARS-

304 CoV-2 PCR-positive patients were plotted against day post symptom onset.
305 Immunocompromised patients are shown in blue. In **(D, E)**, for patients with multiple same-day
306 samples, the sample with the highest S/C value is plotted. **(G)** For the 6 SARS-CoV-2 PCR-
307 positive patients whose IgM, IgG, and NT80 seroconversion events were captured during serial
308 sampling, the days post-symptom onset seroconversion events are compared. **(H)** NT80 activity
309 was evaluated per patient for the indicated time frames post onset of symptoms. The percent of
310 patients with detectable NT80 activity measured within each time frame is indicated below the
311 graphs. If multiple samples per patient were collected, the sample with the highest NT80 value
312 within each time frame was used. **(I)** The average NT80 activity (right axis) and IgG and IgM
313 (left axis) levels are plotted by day post-symptom onset (left); corresponding graphs for
314 individual patients are shown in a 3x3 grid (right). If multiple samples per patient were collected,
315 the sample with the highest S/C or NT80 value per time frame was used.

316

317 **Table S1:** Baseline demographic characteristics, presenting symptoms, chronic medical
318 conditions, medications, and radiographic findings of 43 SARS-CoV-2 PCR-positive UCSF
319 outpatients and hospitalized patients.

320

321 **Table S2:** Descriptive demographic characteristics of individuals who donated blood at San
322 Francisco Bay Area community blood centers (Vitalant Research Institute).

323

324 **References**

325

326 1. Zhu, N. *et al.* A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N. Engl.*

327 *J. Med.* **382**, 727–733 (2020).

328 2. Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons From the Coronavirus

329 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72,314 Cases From

330 the Chinese Center for Disease Control and Prevention. *J. Am. Med. Assoc.* (2020)

331 doi:10.1001/jama.2020.2648.

- 332 3. Yang, X. *et al.* Clinical course and outcomes of critically ill patients with SARS-CoV-2
333 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet*
334 *Respir. Med.* (2020) doi:10.1016/S2213-2600(20)30079-5.
- 335 4. Abbott Laboratories. SARS-CoV-2 IgG [package insert]. (2020).
- 336 5. Bryan, A. *et al.* Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG
337 Assay and Seroprevalence in Boise, Idaho. *J. Clin. Microbiol.* (2020)
338 doi:10.1128/JCM.00941-20.
- 339 6. Long, Q.-X. *et al.* Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat.*
340 *Med.* 1–4 (2020) doi:10.1038/s41591-020-0897-1.
- 341 7. Zhao, J. *et al.* Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease
342 2019. *Clin. Infect. Dis.* (2020) doi:10.1093/cid/ciaa344.
- 343 8. Corman, V. M. *et al.* Viral Shedding and Antibody Response in 37 Patients With Middle
344 East Respiratory Syndrome Coronavirus Infection. *Clin. Infect. Dis.* **62**, 477–483 (2016).
- 345 9. Hsueh, P.-R., Huang, L.-M., Chen, P.-J., Kao, C.-L. & Yang, P.-C. Chronological evolution
346 of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated
347 coronavirus. *Clin. Microbiol. Infect.* **10**, 1062–1066 (2004).
- 348 10. Sun, B. *et al.* Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19
349 patients. *Emerg. Microbes Infect.* **0**, 1–36 (2020).
- 350 11. Whitman, J. D. *et al.* Test performance evaluation of SARS-CoV-2 serological assays.
351 Preprint at <https://www.medrxiv.org/content/10.1101/2020.04.25.20074856v1> (2020).
- 352 12. Bendavid, E. *et al.* COVID-19 antibody seroprevalence in Santa Clara County, California.
353 Preprint at <https://www.medrxiv.org/content/10.1101/2020.04.14.200624363v2> (2020).

- 354 13. Sood, N, *et al.* Seroprevalence of SARS-CoV-2-specific antibodies among adults in Los
355 Angeles County, California, on April 10-11, 2020. *JAMA*, doi: 10.1001/jama.2020.8279
356 (2020).
- 357 14. Hogan, C. A., Sahoo, M. K. & Pinsky, B. A. Sample Pooling as a Strategy to Detect
358 Community Transmission of SARS-CoV-2. *J. Am. Med. Assoc.* (2020)
359 doi:10.1001/jama.2020.5445.
- 360 15. Ortho Clinical Diagnostics. VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total
361 test [package insert]. (2020)
- 362 16. Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is
363 Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280.e8 (2020).

364

365 **Acknowledgments**

366 We thank the patients and their families at UCSF without whom collecting and providing this
367 aggregate data would not have been possible.

368

369 **Competing Interests**

370 CYC is the director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC) and
371 receives research support funding from Abbott Laboratories. JP, MD, KC, SP, and JRH, Jr. are
372 employees of Abbott Laboratories. The other authors have no competing interests to declare.

373

374 **Contributions**

375 C.Y.C. conceived, designed, and supervised the study. D.L.N., and G.M.G. coordinated the
376 study. D.L.N., G.M.G., B.R.S., A.G.L., S.P.B., J.B., and C.Y.C. analyzed data, designed figures,
377 and wrote and edited the manuscript. A.S.G., V.S., C.S.S.M., A.G., D.R.G., E.H., W.G., Y.A.S.,
378 C.W., K.R., J.H., F.A., L.P., C.-Y.O., C.M.L. contributed to the collection of clinical specimens.
379 K.S., T.K., and E.C.T. coordinated clinical sample collection and IgG testing. S.M. provided
380 clinical data and facilitated sample collection. L.M.H., K.T., N.A., D.N.N., N.M.N., and D.Q.

381 performed chart review. M.S., B.C., V.G., P.W., M.B., and J.D.W. coordinated blood donor
382 samples and data. S.Z., L.D., G.S., and S.K.P. performed neutralizing antibody assays. J.M.C.H.,
383 J.P., M.R., K.C., and S.P. performed IgG and IgM testing and provided data establishing testing
384 characteristics of SARS-CoV-2 IgG and IgM assays. N.K.H. performed biostatistical analysis
385 and review. All authors read the manuscript and agreed to its contents.

386

387 **Funding**

388 This work was funded by NIH grants R01-HL105704 (CYC) from the National Heart, Lung, and
389 Blood Institute, R33-129077 (CYC) the National Institute of Allergy and Infectious Diseases, the
390 Charles and Helen Schwab Foundation (CYC). These funders had no role in study design, data
391 collection and analysis, writing the manuscript, or decision to publish. This work was also
392 funded in part by Abbott Laboratories. Employees of Abbott laboratories (J.P., M.R., K.C., S.P.,
393 J.H.) contributed to sample collection, IgG and IgM testing, and data analysis but had no role in
394 the study design, writing the manuscript, or decision to publish.

395

396 **Data Availability**

397 Raw data used in this study, including de-identified patient metadata and test results, are
398 available upon request.

399



